



**NANCY M. ALBERT, MSN, RN, CCRN, CNA\***

Clinical outcomes researcher, clinical nurse specialist, Kaufman Center for Heart Failure, Cleveland Clinic

**JAMES B. YOUNG, MD\***

Medical Director, Kaufman Center for Heart Failure; Head, Section of Heart Failure and Cardiac Transplant Medicine, Department of Cardiology, Cleveland Clinic

# Heart failure disease management: A team approach

## ABSTRACT

Patients with heart failure do better if they are treated in a formal heart failure disease-management program than if they receive standard care: their hospitalization rates and costs of treatment are lower, and their functional status is higher. The programs feature close coordination between primary care givers, subspecialty consultants, and nurses with specialty training in the nuances of heart failure management. Aggressive medical therapy must be coupled with patient education and rapid response to early identified problems. This article reviews the principles of heart failure disease-management programs and cites evidence that they are beneficial.

## KEY POINTS

If crises are to be avoided, the management of heart failure patients must shift from simply ameliorating symptoms to more complex disease management.

The optimal approach to treating heart failure uses an interdisciplinary team: a primary care provider, cardiologist (heart failure specialist), nurse, pharmacist, dietary personnel, and others.

Heart failure treatment requires a synchronized pharmacologic and nonpharmacologic approach.



### PATIENT INFORMATION

**What you can do to keep your heart failure under control, page 63**

\*Ms. Albert has indicated that she has received grant or research support from SmithKline Beecham Pharmaceuticals; Dr. Young has indicated that he has received grant or research support from SmithKline Beecham Pharmaceuticals, Astra-Zeneca, Scios, Bristol-Myers, Roche, Novartis, and Medtronic.

**T**O TREAT HEART FAILURE effectively you need a team and you need a plan. In short, you need a program.<sup>1</sup>

Although some may decry such an approach as “cookbook medicine,” the proof is in the outcomes. Studies show that patients treated in formal programs have lower hospitalization rates, fewer emergency visits, and a higher quality of life, functional status, and level of satisfaction with their care.<sup>1</sup> They also incur less cost.

With a team in place, you can delegate work. Nurses keep in contact with the patients at home on a regular basis, heading off problems before they become crises. Heart failure specialists and others are available if you need them. Furthermore, with a formal plan you know that you are following evidence-based guidelines,<sup>2–5</sup> and not just shooting from the hip. And with a program you can be proactive instead of reactive: you can concentrate on keeping patients healthy, instead of dealing only with acute exacerbations.

A team approach to heart failure management can be implemented in most traditional or managed-care outpatient settings.

## WHAT'S WRONG WITH THE TRADITIONAL APPROACH?

In the traditional approach, the patient comes to the physician (or, too often, to the emergency department of the local hospital) with symptoms such as worsening fatigue or shortness of breath, which the physician tries to resolve. Then the patient goes home, and nobody gives him or her much thought until the next bout of worsening symptoms.

This approach does not work very well. Despite advances in understanding the bio-

TABLE 1

**Common errors and omissions in treating heart failure****Medication-related**

- Failure to prescribe angiotensin-converting enzyme inhibitors or beta-blockers, or use in suboptimal doses
- Suboptimal dosing of diuretics when volume overload (which may be subclinical) persists
- Failure to remove detrimental medications from the regimen
- Inappropriate heart failure treatment in patients with normal systolic left ventricular function (diastolic dysfunction)

**Related to concomitant diseases**

- Failure to control ischemia, hypertension, diabetes, thyroid dysfunction, anemia, or electrolyte disturbances
- Uncontrolled atrial fibrillation; excessive tachycardia or bradycardia
- Failure to discuss and promote cardiovascular and general "disease prevention" strategies (eg, flu shots, lipid-lowering drugs, alcohol or substance abuse withdrawal) when needed

**Related to management strategy**

- Inadequate patient education, eg, inadequate self-care instructions, especially on how to manage new or worsening symptoms
- Failure to recognize or address patient noncompliance
- Failure to assess the option of revascularization if the patient has coronary artery disease
- Failure to consider the option of mitral valve repair if the patient has mitral valve insufficiency
- Delay in referring the patient for cardiac transplantation if indicated
- Delay in obtaining a consult with a heart failure specialist when the patient has had multiple hospital readmissions or symptoms refractory to maximum medical therapy
- Inadequate promotion of cardiac rehabilitation or active exercise
- Inadequate use of specialty community programs for heart failure (eg, a home health care program) when the patient meets inclusion criteria
- Failure to respond promptly and intervene early when the patient initiates contact for a worsening condition

**Physicians  
often do not  
address chronic  
issues that  
affect  
outcome**

chemical abnormalities in heart failure and in its treatment, the morbidity and mortality rates have not budged over the past decade. Further, hospitalization rates and costs have increased. Why should this be?

**The focus is on symptoms.** The primary goal of the traditional approach is to alleviate symptoms. Decreasing morbidity and improving survival are also goals, but get short shrift. Most physicians do not intently focus on nonacute issues such as psychosocial problems, poverty, poor nutrition, poor function, low education level, poor prognosis, problems with self-management, or cardiovascular risk factors such as dyslipidemia.<sup>6,7</sup> Yet these factors can affect compliance and outcomes.

**Patients may not be able to comply with their treatment.** The treatment of heart failure is complex and includes both lifestyle changes (such as exercise and limiting the amount of sodium in the diet) and complicated multidrug regimens. Without ongoing support and encouragement, many patients cannot or will not comply, owing to comorbid conditions, drug side effects, complexity of the regimen, psychosocial issues, physical limitations (due to heart failure or aging or both), or cognitive dysfunction.<sup>1</sup>

**Physicians may not follow guidelines.** Although evidence-based guidelines exist,<sup>2-5</sup> they can be time-consuming to follow and require ongoing follow-up monitoring, which



## Heart failure disease management program used at the Cleveland Clinic




FIGURE 1

may not be feasible in a traditional outpatient office practice. Furthermore, it is likely that many physicians do not know about the guidelines.

**Use of ACE inhibitors.** For instance, angiotensin-converting enzyme (ACE) inhibitors—indicated in all patients with left ventricular systolic dysfunction who have no contraindications to them—tend to be underprescribed or used in suboptimal doses. Philbin<sup>8</sup> and Gattis et al<sup>9</sup> found that ACE inhibitors were underused in the community setting, primarily in the elderly and in patients with perceived (but not actual) contraindications to these drugs. Even though patients older than 74 years were similar to younger patients in their baseline characteristics, they differed in the medications they were prescribed. Of importance, elderly patients who were receiving target doses of ACE inhibitors (ie, those used in clinical trials—generally the equivalent of 20 mg of enalapril daily) appeared to have fewer morbid heart failure events.<sup>9</sup> Other studies confirmed that heart failure medications are generally used in doses lower than those used in clinical trials.<sup>10</sup>

**Other problems.** Other errors or omissions include suboptimal use of other heart failure medications and failure to control concomitant conditions or to address other issues (TABLE 1).<sup>11,12</sup>

#### ■ HEART FAILURE DISEASE MANAGEMENT DEFINED

In an effort to provide better care, doctors, nurses, and others at a number of hospitals set up special disease-management programs for patients with heart failure.<sup>13</sup> Results were good: in general, hospitalizations and emergency visits for heart failure decreased, and functional status, peak oxygen consumption, and quality-of-life scores improved.<sup>14–17</sup>

The programs had key elements in common:

- A multidisciplinary team
- Practice guidelines developed by consensus
- Adjunctive programs
- Patient education
- Systems for following patients at home (“vigilance monitoring”)
- Data collection at regular intervals to measure outcomes.

#### A multidisciplinary team

The heart failure team comprises a number of players. Of note: the lines of authority and communication among these people need to be agreed on and drawn up in the program plan, as should the paths that patients will follow from one team member to the other (FIGURE 1). Good communication is essential among the team members and the patient.

**The primary care physician** is the anchor of the team, the person with whom the patients have the strongest relationship, and the person who orchestrates care decisions that the other team members carry out.

As the “gatekeeper” in managed care, the primary care physician traditionally controls access to specialists. In a heart failure disease-management program, the primary care physician also plays this role, but with the help of algorithms and protocols to improve outcomes. Primary care physicians provide most of the care for patients with heart failure. Even in the hospital, cardiologists care for fewer than one third of all patients admitted for congestive heart failure. In fact, the cardiologist may refer patients to the primary care physician once guideline recommendations are implemented. In this way, patient referrals move both to and from specialty and primary care physicians.

In developing the program, the primary care physician must assure that the program is flexible and can respond to environmental, cultural, and individual patient diversity. For example, if the patients seen in a particular practice are mostly poor, they may need a formal social work program; if they are mostly frail and elderly with multiple comorbidities, they may need office-based pharmacist support; if they tend to consume a lot of salt in the diet, they may benefit from dietitian support.

**The cardiologist.** It is important to have access to a cardiologist with additional training and expertise in managing patients with particularly difficult problems, such as those with multiple hospital admissions over a short period. Heart failure specialists generally have much experience in the aggressive care of very advanced heart failure syndromes, since the cornerstone of their practice is usually patient referral for heart transplantation. In addition, they are more likely to promote alternative

**ACE inhibitors  
tend to be  
underused, or  
used in  
suboptimal  
doses**



options such as experimental drugs or emerging surgical procedures that might be suitable for very ill patients.

Since cardiologists who specialize in heart failure are still relatively rare, networks should be developed that allow primary care physicians or general cardiologists ready access to this additional consultation resource.

**The heart failure specialist** can be instrumental in developing and updating the clinical practice guidelines or care pathways used in the outpatient setting by the primary care provider. In helping develop the protocol, the heart failure specialist should help interpret and communicate published guidelines and ensure that the program is research-based and aggressive and provides the best opportunity to improve outcomes.

**The cardiac nurse.** Many successful programs use cardiac-trained nurses to assist in patient management.<sup>13–17</sup> In one inpatient program,<sup>18</sup> total hospital costs were significantly lowered and length of hospital stay decreased in the year after a nurse practitioner was added to the team. Cardiac nurses have also been incorporated into programs at cardiomyopathy clinics, and the reported outcomes have been good.<sup>14,15,17,19</sup> In an aggressive, nurse-assisted management program, outpatient visits and communication should increase, whereas hospital readmission rates will likely decrease.

Under the supervision of the primary care physician, an advanced-practice nurse (clinical nurse specialist or nurse practitioner) can have a comprehensive role on the team, providing much of the patient care as guided by protocols and guidelines, and acting as the facilitator and communicator between the other team members (TABLE 2).

**Other team members** include emergency medicine specialists, pharmacists, nutritionists, dietitians, cardiac rehabilitation personnel, social workers, home health care aides, and palliative care specialists.

### Practice guidelines

The protocols should be based on national guidelines and cover the following areas.

**Seeking evidence of underlying disease,** such as coronary artery disease or cardiomyopathy.

**TABLE 2**

### **Role of the advanced-practice nurse in disease management for heart failure**

Ensures that primary and secondary atherosclerosis prevention strategies are in place

Assesses the patient's knowledge of heart failure and its management, and patient education needs

Provides patient education

Assesses patient compliance with therapy, and reviews patient management and compliance issues with the primary care physician

Determines need for medication changes on the basis of symptoms

Ensures therapeutic dosing of drugs is appropriate

Performs routine follow-up care and monitoring

Supervises data collection and performs outcomes analysis

Troubleshoots worsening symptoms

Schedules frequent (weekly or biweekly) patient visits to assess readiness for medication up-titration

Consults with the primary care physician regarding problems, and facilitates ad hoc consultation with the heart failure specialist

Facilitates referral of patients from the heart failure specialist to the primary care physician for continued follow-up, surveillance, and implementation of general preventive health care guidelines, such as screening for lipid abnormalities or malignancy and administration of appropriate vaccines

**Nonpharmacologic therapy** such as diet, fluid management, activity and exercise, and lifestyle modifications.

**Pharmacologic therapy**, including ACE inhibitors (FIGURE 2) and beta blockers (FIGURE 3), if indicated, in the right doses. Numerous reports<sup>14,17,20–24</sup> document the benefit of polypharmacy protocols.

**Indications for obtaining a consult with a heart failure specialist** and for hospitalization (TABLE 3).

### Adjunctive programs

The program should have access to a subacute care facility, a rehabilitation unit, an emergency center clinical decision unit, and a heart failure intensive care unit. Specific heart failure protocols should be developed for

## ACE inhibitor therapy algorithm used at the Cleveland Clinic

### DOES THE PATIENT HAVE SYSTOLIC HEART FAILURE?

**NO** Individualize vasodilator therapy on the basis of restrictive physiology (diastolic dysfunction), renal function, and blood pressure

### YES Does the patient have any of the following?

- Serum creatinine  $\geq 3.0$  mg/dL
- History of intolerance to ACE inhibitors (eg, angioedema, severe hypotension, hyperkalemia, severe persistent cough)
- Already taking ACE inhibitor at target dose or maximum tolerated dose

### YES Begin hydralazine-nitrate combination:

- Hydralazine (Apresoline) 25 mg three or four times a day, increased to maximum of 100 mg four times a day in 25-mg increments every 24 hours as necessary,  
plus
- Isosorbide dinitrate (Isordil) 10 mg three times a day increased to maximum of 80 mg three times a day in 20-mg increments every 24 hours as necessary. If tolerating isosorbide dinitrate, may switch to isosorbide mononitrate (Imdur) 30 mg daily, increased to maximum of 240 mg daily in increments every week in doses as follows: 30, 60, 90, 120, 180, 240 mg

*Note:* If renal function is adequate, may consider an angiotensin II receptor blocker in addition to an ACE inhibitor or as substitute for hydralazine-nitrate combination or for ACE inhibitor intolerance

### NO Is serum sodium < 134 mg/dL?

#### YES Assess for volume overload; if present:

- Give diuretic
- Reassess sodium, potassium, and magnesium levels
- Restrict fluids and free water to 1,500 cc/day for 3 days

*Note:* Hypotension with ACE inhibitors is less likely when serum sodium is > 134 mg/dL

### NO Is systolic blood pressure < 80 mm Hg, or does patient have signs of orthostasis with vasodilator therapy?

#### YES Do not begin new vasodilator therapy or increase dose of current therapy

#### NO Begin ACE inhibitor or increase dose using incremental table below until target is reached

## ACE inhibitor incremental dosing schedule

| SELECTED AGENTS*               | DOSES<br>PER DAY | MG PER DOSE |        |        |        |        |         | INTERVAL<br>BETWEEN STEPS |
|--------------------------------|------------------|-------------|--------|--------|--------|--------|---------|---------------------------|
|                                |                  | STEP 1      | STEP 2 | STEP 3 | TARGET | STEP 5 | MAXIMUM |                           |
| Captopril (Capoten)            | 3                | 6.25        | 12.5   | 25     | 50     | 75     | 100     | 48 hours                  |
| Enalapril (Vasotec)            | 2                | 2.5         | 5.0    | 7.5    | 10     | 15     | 20      | 1 week                    |
| Lisinopril (Prinivil, Zestril) | 1                | 5           | 10     | 15     | 20     | 30     | 40      | 1 week                    |
| Quinapril (Accupril)           | 2                | 5           | 10     | 15     | 20     | —      | 20      | 1 week                    |
| Ramipril (Altace)              | 1                | 1.25        | 2.5    | 5      | 10     | —      | 10      | 1 week                    |

*Note:* Aspirin may diminish ACE inhibitor response; low-dose aspirin (eg, 81 mg) may be reasonable

\*Not shown: benazepril (Lotensin), fosinopril (Monopril), moexipril (Univasc), trandolapril (Mavik), which are not approved by the FDA for treating heart failure

**FIGURE 2.** Angiotensin-converting enzyme (ACE) inhibitor therapy algorithm and incremental dosing schedule for patients with systolic heart failure.



use in these settings to ensure aggressive and effective therapies that are congruent with the disease-management objectives and ensure ongoing communication and collaboration.

### Patient education, compliance, and self-management

Patients should learn the warning symptoms of worsening heart failure and what to do should these occur (see the **Patient Information** page, “What you can do to keep your heart failure under control,” page 63). They should be encouraged to use alternatives to emergency facilities. The goal is to prevent crises by carefully following patients and intervening early when fluid retention and other symptoms first develop.

Sodium retention due to inadequate dietary restriction is a leading cause of hospitalization in heart failure.<sup>25</sup> Butler et al<sup>26</sup> found that over half of heart failure admissions to a university medical center were for dyspnea without other life-threatening complications. These patients were thought to be at low risk and could likely have been cared for in a nonacute care setting, had that been available. These reports reinforce the need for programs that offer aggressive advice and comprehensive education about patient self-management. Program-specific written material is particularly useful.

### Management outside the office

Comprehensive management does not necessarily have to be carried out in the traditional office setting.

**Telemanagement** is simple and inexpensive and provides a means of collecting data for measuring outcomes. The information gathered may lead to adjustments to the patient’s plan of care or help optimization of program objectives.

One group<sup>27</sup> carried out weekly telephone contact for 6 weeks after an initial home nursing visit. Program objectives were to promote optimal doses of vasodilators and other heart failure drugs, keep patients compliant with a low-sodium diet, and watch them for worsening heart failure or clinical instability as reflected by weight gain, edema, or symptoms. At 6 months, dietary sodium intake had fallen, average medication doses had increased,

**TABLE 3**

## Indications for referral or for hospitalization

### Indications for referral to a heart failure specialist

Frequent decompensation to New York Heart Association (NYHA) class III or IV

Refractory NYHA III or IV heart failure without obvious contraindications to heart transplantation

Poor quality of life (patient may be a candidate for research medication protocols)

Persistent symptoms despite an optimized medication regimen (which may require home inotrope therapy or surgery)

Frequent hemodynamic instability, electrolyte imbalance, arrhythmias, bouts of mental obtundation, or emergency room visits

Refractory angina with heart failure

Frequent bouts of respiratory fatigue

Acute pulmonary edema

Acute hospitalization in a coronary care unit with pulmonary artery catheter insertion to guide aggressive therapy.

### Indications for hospitalization

Hypotension with organ dysfunction

Severe dyspnea or periodic respirations

Profound fluid retention states

Severe renal or hepatic insufficiency

Hemodynamic instability requiring intravenous inotropes

Arrhythmias requiring intravenous antiarrhythmic treatment or malignant arrhythmias

Decompensated heart failure with refractory angina

Elevated cardiac enzymes or electrocardiographic signs of myocardial ischemia, injury, or new necrosis

functional status and exercise capacity had improved, and hospitalization and emergency department visits had decreased.

**e-Management.** Telemanagement can be time-intensive and may not be practical in a busy outpatient practice. Technology may provide an answer: healthcare companies now provide computer programs for communicating with patients. For example, patients may log on to the hospital’s web site every day and fill out a form that includes their weight and

## Beta-blocker therapy algorithm used at the Cleveland Clinic

### DOES THE PATIENT HAVE SYSTOLIC HEART FAILURE?

**NO** Individualize beta-blocker therapy on the basis of restrictive physiology (diastolic dysfunction), hypertension, coronary artery disease, tachyarrhythmias

**YES** What is the patient's New York Heart Association class?

■ **I (asymptomatic). Does the patient have any of the following?**

- Marked left ventricular dysfunction (ejection fraction < 35%)
- History of hypertension
- Coronary artery disease or previous myocardial revascularization

**YES** Consider beta-blocker therapy *after* stabilizing therapy with an ACE inhibitor or other vasodilator, a diuretic, and digoxin for 2–3 weeks

**NO** Beta-blocker use is unclear but possibly beneficial

■ **II (mild) or III (moderate). Is the patient taking an ACE inhibitor, other vasodilator, a diuretic, and digoxin?**

**NO** Stabilize therapy with an ACE inhibitor or other vasodilator, diuretic, and digoxin for 2–3 weeks before considering a beta-blocker

**YES** Does the patient have a contraindication to beta-blockers, eg, any of the following?

- Significant hepatic impairment
- Hospitalization or major cardiovascular event in the last 7 days that involved hypervolemia or Killip class  $\geq 2$  as part of problem
- Significant hypotension
- Currently receiving an intravenous inotrope
- Current light-headedness or dizziness
- History of clinically significant asthma, bronchitis, or other bronchospastic condition
- Resting heart rate < 50 or a consistent heart rate < 60–65 with symptoms
- History of sick sinus syndrome or 2nd or 3rd degree AV block without a permanent pacemaker in place

**YES** Do not begin beta-blockers; if the patient is already taking a beta-blocker, do not increase the dose—consider decreasing the dose

**NO** Begin carvedilol\* at 3.125 mg twice a day for 2 weeks, regardless of weight and age  
Have patient take with food and take first dose at bedtime to minimize orthostatic hypotension; provide proper instruction on signs and symptoms of congestive heart failure and what to report

- If dose is tolerated, increase to 6.25 mg twice a day for 2 weeks
- Double the dose every 1–4 weeks, to a target dose of 25 mg twice a day for patients weighing  $\leq 85$  kg or 50 mg twice a day for patients weighing > 85 kg

■ **IV (severe). Begin a beta-blocker following the guidelines above *only if patient is euolemic*; up-titrate drug *slowly*; monitor patient closely**

### Beta-blocker incremental dosing schedule

| SELECTED AGENTS*       | DOSES<br>PER DAY | MG PER DOSE     |                                       |                                       | SIDE EFFECTS                                                                                 |
|------------------------|------------------|-----------------|---------------------------------------|---------------------------------------|----------------------------------------------------------------------------------------------|
|                        |                  | INITIAL         | TARGET                                | MAXIMUM                               |                                                                                              |
| Carvedilol (Coreg)     | 2                | 3.125           | 25 ( $\leq 85$ kg)<br>50 ( $> 85$ kg) | 25 ( $\leq 85$ kg)<br>50 ( $> 85$ kg) | Bradycardia, hypotension, AV block, worsening heart failure, bronchospasm, dyspnea, diarrhea |
| Metoprolol (Toprol XL) | 1                | 25 <sup>†</sup> | 150–200                               | 200                                   | Same as for carvedilol, but not diarrhea                                                     |
| Metoprolol (Lopressor) | 2                | 25 <sup>†</sup> | 50                                    | 100                                   | Same as for carvedilol, but not diarrhea                                                     |
| Bisoprolol (Zebeta)    | 1                | 1.25            | 5 ( $\leq 85$ kg)<br>10 ( $> 85$ kg)  | 20                                    | Same as for metoprolol, plus vivid dreams                                                    |

\*Carvedilol is currently the only beta-blocker approved by the Food and Drug Administration (FDA) for treating heart failure, but clinical trials of bisoprolol and metoprolol<sup>33,34</sup> indicate morbidity and mortality benefit as well

<sup>†</sup>One tablet cut in half

**FIGURE 3.** Beta-blocker therapy algorithm and incremental dosing schedule for patients with systolic heart failure.

yes-or-no questions about their symptoms and self-management. Registered nurses monitor the data and notify the patient's care providers immediately if they encounter any "alarm" values.

**Home visits.** In one study,<sup>28</sup> patients received either unstructured usual care or a single home visit 1 week after hospital discharge. A nurse and pharmacist assessed their knowledge of medications and the extent of medication compliance. If problems were identified, incremental monitoring and other resources were focused on the patient. Patients in the home-intervention group had significantly fewer unplanned readmissions and a trend toward decreased mortality.<sup>28</sup>

**Mailings.** Another strategy is to mail educational material to the patient every month. These should be easy to read and understand. In one study,<sup>29</sup> patients received mailings on heart failure, medications, risk factors, and behavioral health issues that reinforced key behavioral objectives and provided information on emotional health and the chronic nature of heart failure. Compared with a control group, the group receiving the mailings complied better with their dietary salt restriction and medications, and they felt more confident about their self-management abilities. Perhaps most importantly, readmission rates were reduced by 51% in the intervention group.

**"Group therapy"** has also been used successfully to reduce adverse outcomes in patients with heart failure. In one study,<sup>30</sup> patients randomized to a lifestyle modification program consisting of structured exercise, cognitive-behavioral therapy, and dietary modification had significant improvement in exercise tolerance, weight loss, and depression and anxiety scores.

### **Rapid-response medical advice systems provide 24-hour access**

Patients with chronic heart failure may benefit from a telephone-based rapid response program that provides 24-hour access to medical advice and interventions. This program adjunct uses algorithms or protocols to treat new or worsening symptoms after assessing the patient's medical, medication, diet, fluid, and exercise history.

A rapid-response program may decrease the need for emergency care and emergent inpatient hospitalization, especially if patients are instructed to use the program for early symptoms of worsening condition. If so, this would be a good trend: the hospital admission rate for patients with heart failure actually increased in the 1990s, making heart failure (DRG 127) the number-one hospital discharge diagnosis in the elderly and the most costly Medicare diagnosis to treat.<sup>31</sup>

There are many ways to set up a rapid-response system. In an established nurse-on-call program, algorithms can include care options that move beyond the standard advice to have the patient seek emergency department care or contact the office for a next-day appointment. An algorithmic program can also be developed for use with a pager system monitored by a cardiac nurse. A local emergency department can place a dedicated telephone line in the triage area. The triage nurse would offer advice to patients by following written protocols. Based on available evidence of telemanagement program benefits, it seems reasonable to recommend a rapid-response intervention system to augment services for heart failure patients during off-duty hours.

### **Measuring outcomes**

The following data should be gathered at regular intervals to measure the effectiveness of the program:

**Baseline information** such as age, gender, race, education level, social resources, etiology of heart failure, comorbidities, signs, and symptoms.

**What was done?** Did the team comply with quality-of-care definitions? What medications were used? What were the reasons for discontinuing, changing, or failing to up-titrate drugs? How were worsening symptoms treated? Were multidisciplinary services used? Were hemodynamic parameters measured?

**What were the outcomes?** Examples: changes in functional class, costs of care, hospitalization rates (number of admissions, number of repeat admissions, length of stay, use of the emergency department), changes in patient practices (eg, use of a rapid-response system rather than the emergency department; changes in sodium intake), proportion

**Without a plan, needed care may be omitted**



of patients eligible for therapies who actually received them, quality-of-life data (eg,

Minnesota Living With Heart Failure questionnaire),<sup>32</sup> symptoms, survival rates. 

## REFERENCES

1. Rich MW. Heart failure disease management: A critical review. *J Cardiac Failure* 1999; 5:64–75.
2. Packer M, Cohn J. Consensus recommendations for the management of chronic heart failure. *Am J Cardiol* 1999; 83(2A):1A–38A.
3. Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure. *Circulation* 1995; 92:2764–2784.
4. Konstam M, Dracup K, Baker D, et al. Heart failure: Evaluation and Care of Patients with Left-Ventricular Systolic Dysfunction. Clinical Practice Guideline No. 11. AHCPR Publication No. 94-0612. Rockville, MD: Agency for Health Care Policy and Research, Public Health Service, U.S. Department of Health and Human Services. June 1994.
5. Heart Failure Society of America. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction—pharmacological approaches. *J Cardiac Failure* 1999; 5:357–382.
6. Hanumanthu S, Smith J, Kelly C, Wilson JR. Physician compliance with key guidelines for the management of heart failure continues to be poor [abstract]. *J Cardiac Failure* 1998; 4(Suppl 1):54.
7. Dahle K, Webb J, Chomsky D, Wilson JR. A screening tool to identify nonacute problems in chronic heart failure patients [abstract]. *J Cardiac Failure* 1998; 4(Suppl 1):55.
8. Philbin E. Factors determining angiotensin-converting enzyme inhibitor underutilization in heart failure in a community setting. *Clin Cardiol* 1998; 21:103–108.
9. Gattis WA, Larsen RL, Hasselblad V, Bart BA, O'Connor CM. Is optimal angiotensin-converting enzyme inhibitor dosing neglected in elderly patients with heart failure? *Am Heart J* 1998; 136:43–48.
10. Ramahi TM, Rohlf K, Sheynberg N, Nystrom KV, Cabin J. Effect of heart failure program on cardiovascular drug utilization in patients with chronic heart failure [abstract]. *J Cardiac Failure* 1998; 4(Suppl 1):58.
11. Mills RM, Young JB, editors. Practical Approaches to the Treatment of Heart Failure. Baltimore, MD: Williams & Wilkins, 1998.
12. Stevenson LW, Massie BM, Francis GS. Optimizing therapy for complex or refractory heart failure: a management algorithm. *Am Heart J* 1998; 135:S293–S309.
13. Schulman KA, Mark DB, Califf RM. Outcomes and costs within a disease management program for advanced congestive heart failure. *Am Heart J* 1998; 135:S285–S292.
14. Fonarow GC, Stevenson LW, Walden JA et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. *J Am Coll Cardiol* 1997; 30:725–732.
15. Hanumanthu S, Butler J, Chomsky D, Davis S, Wilson JR. Effect of a heart failure program on hospitalization frequency and exercise tolerance. *Circulation* 1997; 96:2842–2848.
16. Shaw NB, Der E, Ruggerio C, Heidenreich PA, Massie BM. Prevention of hospitalizations for heart failure with an interactive home monitoring program. *Am Heart J* 1998; 135:373–378.
17. Smith LE, Fabbri SA, Pai R, Ferry D, Heywood T. Symptomatic improvement and reduced hospitalization for patients attending a cardiomyopathy clinic. *Clin Cardiol* 1997; 20:949–954.
18. Dahle KL, Smith JS, Ingersoll GL, Wilson JR. Impact of a nurse practitioner on the cost of managing inpatients with heart failure. *Am J Cardiol* 1998; 82:686–688.
19. Roglieri JL, Futterman R, McDonough KL, et al. Disease management interventions to improve outcomes in congestive heart failure. *Am J Man Care* 1997; 3:1831–1839.
20. Luzier AB, Forrest A, Adelman M, Hawari FI, Schentag JJ, Izzo JL. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. *Am J Cardiol* 1998; 82:465–469.
21. Hobbs RE. High or low doses of ACE inhibitors for heart failure? *Cleve Clin J Med* 1998; 65:539–542.
22. Young JB, Gheorghiade M, Uretsky BF, Patterson H, Adams KF. Superiority of “triple” drug therapy in heart failure: insights from the PROVED and RADIANCE trials. *J Am Coll Cardiol* 1998; 32:686–692.
23. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. *N Engl J Med* 1997; 336:525–533.
24. Young J. Carvedilol for heart failure: renewed interest in beta blockers. *Cleve Clin J Med* 1997; 64:415–422.
25. Bennett SJ, Hustler GA, Baker SL, et al. Characterization of the precipitants of hospitalization for heart failure decompensation. *Am J Crit Care* 1998; 7:168–174.
26. Butler J, Hanumanthu S, Chomsky D, Wilson JR. Frequency of low-risk hospital admissions for heart failure. *Am J Cardiol* 1998; 81:41–44.
27. West JA, Miller NH, Parker KM, et al. A comprehensive management system for heart failure improves clinical outcomes and reduces medical resource utilization. *Am J Cardiol* 1997; 79:58–63.
28. Stewart S, Pearson S, Horowitz JD. Effects of a home-based intervention among patients with congestive heart failure discharged from an acute care hospital. *Arch Intern Med* 1998; 158:1067–1072.
29. Serxner S, Miyaji M, Jeffords J. Congestive heart failure disease management study: A patient education intervention. *CHF* 1998; 4(3):23–28.
30. Kostis JB, Rosen RC, Cosgrove NM, Shindler DM, Wilson AC. Nonpharmacologic therapy improves functional and emotional status in congestive heart failure. *Chest* 1994; 106:996–1001.
31. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. *J Heart Lung Transplant* 1994; 13:S107–S112.
32. Rector TS, Kubo SH, Cohn JN. Patient's self-assessment of their congestive heart failure. Part 2. Content, reliability and validity of a new measure, the Minnesota Living with Heart Failure questionnaire. *Heart Failure* 1993; 3:198–209.
33. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; 353:9–13.
34. Hjalmarson A, Goldstein S, Fagerberg B, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF). *JAMA* 2000; 283:1295–1302.

ADDRESS: James B. Young, MD, Cardiac Catheterization Laboratory, F25, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail youngj@ccf.org.